Treatment of schizophrenia with ergot derivatives

C. A. Tamminga, M. H. Schaffer

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.

Original languageEnglish (US)
Pages (from-to)239-242
Number of pages4
Issue number3
StatePublished - Dec 1 1979


  • Bromocriptine
  • CF 25-397
  • Dopamine
  • Ergot derivatives
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Treatment of schizophrenia with ergot derivatives'. Together they form a unique fingerprint.

Cite this